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We previously established Epstein - Barr virus (EBV)-trans-
formed bullous pemphigoid (BP) patient lymphoblastoid cell 
lines, which produced human monoclonal anti - basement 
membrane zone antibodies. In the present study, we estab-
lished two independent human - human hybridomas by fu-
sion of these EBV transformants with a human B-cell line. 
These hybridomas, designated SE-HY-4B and 10D-HY-BB, 
were very stable and showed a high yield of monoclonal 
antibody (MoAb) secretion. Each cell line was tetraploid and 
showed combined rearranged segments of immunoglobulin 
heavy-chain gene derived from both an EBV transformant 
and a parent cell. Immunoblot analysis showed that the SE-
HY -4B MoAb recognized the 230-kDa BP antigen but that 
the 10D-HY-BB MoAb did not show any reactivity. In con-
B ullous pemphigoid (BP) is an autoimmune skin disease in which subepidermal blisters develop due to dermal-epidermal separation at the basement membrane zone (BMZ) [1]. Anti-BMZ autoantibodies are constantly observed in patient sera [2] and are considered to play 
an important role in the pathogenesis of BP [3-6]. The antigens 
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trast, both MoAbs precipitated the 230-kDa BP antigen with 
immunoprecipitation. These results indicate that the two 
MoAbs reacted with different epitopes on the 230-kDa 
BP antigen: a continuous epitope for the SE-HY-4B MoAb 
and a conformation-dependent epitope for the 10D-HY-BB 
MoAb. This speculation was confirmed at the molecular 
level by the result that the fusion protein produced by a 
partial cDNA for the 230-kDa mouse BP antigen reacted 
with the SE-HY-4B MoAb but not with the 10D-HY-BB 
MoAb. Furthermore, the study of the reactivity with fusion 
proteins of a series of deleted clones restricted the epitope for 
the SE-HY-4B MoAb within the region with 114 amino acid 
residues in the C-terminal domain of the 230-kDa BP anti-
gen.] Invest Dermato1100:310-315, 1993 
with which the anti-BMZ antibodies react have recently been exten-
sively investigated, and a 230-kDa protein present at hemidesmo-
some has been identified as a major BP antigen [7 -12]. 
On the other hand, the cell lines secreting human monoclonal 
antibodies (MoAbs) have been produced mainly by two techniques: 
Epstein-Barr virus (EBV) transformation [13-17] and heterohy-
bridoma or homohybridoma [18-21]' however, the production of 
human MoAb is still very difficult, mainly because of the instability 
ofEBV-transformed cells [14,15] or the low frequency in human-
human hybridomas [20,21]. We previously established three inde-
pendent EBV -transformed cell lines from peripheral blood B cells 
of a patient with BP that produced human anti-BMZ MoAbs [22] . 
Among the MoAbs produced by these three cell lines, designated 
SA, sE, and 10D, the blocking immunofluorescence study indicated 
that the SA and 5E MoAbs recognized the same or closely associated 
epitope, whereas the epitope for the lOD MoAb was distinct. There-
fore, we further analyzed the antigen molecules for the 5E and 10D 
MoAbs by immunoblot technique and found that the 5E MoAb 
reacted with the 230-kDa BP antigen but that the 10D MoAb did 
not show any specific reactivity [22] . These MoAbs have been 
shown to be useful for the characterization of anti-BMZ antibodies 
in the BP sera [22], and the cDNA encoding the 230-kDa BP anti-
gen has been isolated by use of the 5E MoAb [23]. 
.As stated above, however, the type ofEBV-transformed lympho-
blastoid cell line is unstable and readily loses its capacity to prolifer-
ate or to secrete antibody . Indeed, although both the 5E and lOD 
cell lines produced a considerable amount of anti-BMZ antibodies 
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for as long as 6 months, the capacity of these cell lines to proliferate 
and secrete immunoglobulin (Ig) G gradually decreased. In particu-
lar, the 10D MoAb did not show apparent cell growth after recovery 
from frozen storage. 
To resolve this problem, a new method has recently been devel-
oped, in which human lymphocytes are first transformed by EBV 
and subsequently fused with previously immortalized human lym-
phocyte cell lines [24-26]. In th~ present study, we applied this 
technique to rescue MoAb production from our EBV transf~rmants 
and succeeded in establishing more stable hybridomas, deSIgnated 
5E-HY-4B and 10D-HY-SB. Using the MoAbs produced by these 
hybridomas, we further characterized epitopes for these .human 
MoAbs by both immunoprecipitation and recombinant protem tech-
nology. The results suggested that the 5E-HY-4B MoAb reacts 
with a continuous epitope on the 230-kDa BP antigen, whereas the 
10D-HY-SB MoAb recognizes a conformation-dependent epitope 
on the same antigen. Furthermore, the studies of fusion proteins of a 
series of deleted clones of our eDNA for the 230-kDa mouse BP 
antigen [23] restricted the epitope of the SE-HY-4B MoAb with!n 
the region, with 114 amino acid residues in the C-terminal domam 
of the 230-kDa BP antigen. 
MATERIALS AND METHODS 
Cell Lines The preparation and characterization of the EBV-
transformed cell lines producing human anti-BMZ MoAbs were 
described previously [22]. Two of these cell lines, designated 5E and 
10D, were used in the present study. 
The hypoxanthine, aminopterin, thymidine (HAT) -sensitive 
and ouabain-resistant human B-Iymphoid cell line AC-33 was a 
kind gift from Dr. Yuzo Ichimori and Dr. Susumu Iwasa (Central 
Research Division, Takeda Chemical Industries, Ltd., Osaka, 
Japan) that was derived from the TAW-925 cell line [24,27]. The 
AC-33 cells were maintained in RPMI 1640 medium (Gibco Labo-
ratories, Grand Island, NY) containing 10% fetal calf serum (FCS) 
(Gibco), 100,ug/ml penicillin (Gibco), 100,ug/ml streptomycin 
(Gibco), and 100,uM 6-thioguanine (Sigma Chemical Co., St. 
Louis, MO). 
Fusion Procedure Cell fusion was performed according to the 
method described by Ichimori et al [24].5 X 106 EBV transformants 
and 1 X 107 AC-33 cells were mixed, precipitated by centrifuga-
tion, and subsequently suspended in 0.5 ml of 45% polyethylene 
glycol 4000 (E. Merck, Darmstadt, Germany) in RPMI 1640. After 
the cells were incubated for 5 min at 37°C, pre-warmed RPMI 
1640 was added at a speed of 2 ml/min. Cells were precipitated 
again; suspended with 10 ml RPM I 1640 supplemented with 1 X 
10-4 M hypoxanthine, 4 X 10- 7 M aminopterin, 1.6 X 10- 5 
M thymidine, and 10% FCS (HAT medium); and seeded in a vol-
ume of 100 ,ul to each well of a 96-well culture plate (Falcon Plas-
tics, Cockeysville, MD). A 100-,u1 volume of HAT medium supple-
mented with 5 X 10-7 M ouabain was added the next day. A 
half-volume of culture medium was replaced twice with HAT-
ouabain medium and then with 10% FCS - RPMI 1640 every other 
day until colonies were sufficiently grown to be screened for the 
production of autoantibodies by indirect immunofluorescence (IIF) 
using normal human skin as a substrate. Cells in the positive wells 
were cloned by a limiting dilution method using 10% FCS-RPMI 
1640 containing 10% Origen hybridoma cloning factor (Igen, Inc. , 
Rockville, MD). 
Characterization of Hybridomas Chromosomes of estab-
lished hybridomas were analyzed by Giemsa method [28] . Ig heavy-
chain gene rearrangement was studied according to the method 
previously described by Korsmeyer et al [29]. Briefly, high-
molecular-weight genomic DNA was extracted from hybndomas 
and the AC-33 cells; digested to completion with BamHI, BeoRI, 
and HindIII; and hybridized with the JH probe, a 2.4-kb germ-line 
Sau3a fragment. 
Purification of Human MoAbs The established hybridoma 
clones were transferred to and propagated in GIT medium (Nihon 
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Seiyaku, Tokyo, Japan) containing 2 ,ugjml insulin, 2 ,ugjml trans-
ferrin, 2 X 10-8 M sodium selenite, and 3 mg/ml GFS (a 55-70% 
ammonium sulfate fraction of serum from adult cartle) in the basal 
medium (a mixture consisting of an equal volume of Iscove's me-
dium and HAM F12 medium) [30] . After salt precipitation with 
ammonium sulfate, the MoAbs were purified from the culture su-
pernatants by successive chromatography using a DEAE-cellulose 
column (DE 52; Whatman BioSystems Ltd., Kent, England) , a pro-
tein A column (Pharmacia AB, Uppsala, Sweden), and anti-bovine 
serum albumin and anti-GFS antibody-coupled columns, as de-
scribed previously [31] . Purity of the antibodies was determined by 
sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-
pAGE) under reduced condition. IgG concentration was deter-
mined by an enzyme-linked immunosorbent assay using human 
IgG as a standard [27] . The IgG subclass of human MoAbs was 
determined by IIF using anti-human IgG subclass mouse MoAbs 
[32]. 
IIF IIF was performed as previously described [2], using fluores-
cein isothiocyanate - conjugated anti - human IgG rabbit anti-serum 
(Dako, Copenhagen, Denmark) as a second antibody. As a substrate, 
a section of intact or 1.0 M NaCI split normal human skin [33] was 
used without fixation. When KU8 cells, a human squamous cell 
carcinoma cell line derived from penile carcinoma [34] , were used as 
a substrate, cells were cultured on glass coverslips, fixed with ace-
tone for 20 min at - 20°C, and extracted with 0.5% Triton X-100 
in phosphate-buffered saline for 15 min at room temperature [35]. 
After all MoAbs from both transformant cell lines and both hy-
bridoma cell lines were biotinylated, a blocking immunofluores-
cence test was performed by the method described previously [22] . 
Immunoblot Analysis Immunoblotting was performed accord-
ing to the method described previously [22] . 
Immunoprecipitation Immunoprecipitation was performed 
mainly according to the method described by Stanley et al [7]. 
Briefly, KU8 cells were radiolabeled with 35S-methionine 
(0.925 X 106 Bqjml) in the methionine-free medium and lysed 
with 0.5% nonidet P-40 in tris(hydroxymethyl)aminomethane-
H CI- buffered saline. Antigen - antibody complexes were immuno-
precipitated by protein-G Sepharose (Pharmacia). After proteins 
were separated by SDS-PAGE, gels were dried, exposed overnight 
on an image plate, and analyzed using the BAS 2000 image analyzer 
system (Fuji Photo Film Co. Ltd., Kanagawa, Japan). 
Production of Recombinant Proteins BPM1, a partial cDNA 
encoding a C-terminal half of the 230-kDa mouse BP antigen [23] , 
was used for the production of recombinant proteins. The entire 
3.2-kb BeoRI fragment of BPMl was inserted into pUC9, and the 
120-kDa recombinant protein was produced as reported previously 
[36] . Six different DNA fragments [SacI - HindIII (S-H), Xhol-
HindIII (X-H) Xbal-BcoRI (X -E), Xbal-Bc1I (X-Bc), XbaI-StuI 
(X-S), XbaI-Bg1II (X-Bg)] were produced by various restriction 
enzymes. (see later Fig 7 A ). These fragments were subcloned in-
frame into an expression plasmid vector pAT153 (Hasegawa A et aI, 
unpublished, 1991), and fusion proteins with a partial TrpB se-
quence were induced by addition of p-indoleacrylic acid. A DNA 
fragment [Bg1II -Stul (Bg-S)] (see later Fig 7A) was subcloned 
in-frame into an expression plasmid vector pGEX-3X (Pharmacia), 
and a fusion protein with a partial glutathione-S-transferase was 
induced by addition of isopropyl-P-thiogalactopyranoside. Bacte-
rial pellets containing the fusion proteins were lysed by boiling in 
Laemmli's sample buffer and subjected to SDS-PAGE. Blotted ni-
trocellulose sheets were immunostained as described previously 
[36] . 
RESULTS 
Establishment of Hybridomas Secreting Human MoAbs 
Against the BMZ In cultures of both the 5E and 10D transfor-
mants fused with the AC-33 cells, more than 10 wells were found to 
contain colonies. The cells from three wells were cloned by the 
limiting dilution method, and the two largest colonies, designated 
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Figure 1. Ig heavy-chain gene rearrangement patterns in the 5E-HY -4B 
cells (lanes 5E) , the 100-HY-8B cells (lanes tOD), and the AC-33 cells 
(lanes AG). The JH probe consisting of a 2.4-kb germ-line Sau3a fragment 
was hybridized with BamHl-, EcoRI- or HindIII-digested ONAs extracted 
from each cell line. The AC-33 cells show both germ-line (open arrows) and 
one or two rearranged JH segments (closed arrows) in all restriction enzyme 
digests. In addition to these segments, one rearranged segment is discern-
ible in the 5E-HY-4B cells by using the HindIII restriction sites (open 
arrowhead), and two each of the rearranged JH regions are detected in the 
100-HY -8B cells by using the BamHl and HindIIl restriction sites (closed 
arrowheads) . 
5E-HY-4B and 10D-HY-8B, respectively, were further expanded. 
The secretion of anti-BMZ antibody was confirmed by IIF of nor-
mal human skin section for every well with colony formation. 
As mentioned above, although the original 1 OD transformant did 
not show apparent cell growth after recovery from frozen storage, 
the 10D-HY -8B hybridoma demonstrated a very high level of pro-
liferation. The doubling time of the 5E-HY -4B hybridoma deter-
mined by counting cell number was approximately two-thirds of 
that of the original 5E transformant (data not shown) . 
Characterization of Hybridomas' Chromosomal analysis per-
formed for both hybridomas 6 months after the cell isolation re-
vealed that both cell lines were tetraploid with slight aneuploidy. 
The 5E-HY-4B cells indicated a karyotype with a range of90-93 
and a modal number of 92; the 10D-HY-8B cells showed a karyo-
type with a range of 85 - 92 and a modal number of 87. 
To further determine that each cell line is really a hybridoma of 
the corresponding original transformant with an AC-33 cell, Ig 
heavy-chain gene rearrangement analysis was performed (Fig 1). 
The AC-33 cells showed a germ line and one or two rearranged JH 
segments in BamHI-, EcoRI-, and Hindlll-digested genomic DNAs. 
In addition to these segments, the 5E-HY -4B cells showed a differ-
ent rearranged segment in Hindlll-digested DNA. For the 10D-
HY -8B cells, two each of specific rearranged segments were seen in 
BamHI- and HindlIl-digested DNAs. 
Purification of Human MoAbs Through a series of purifica-
tion procedures, 6 liters of GIT medium supernatant from each of 
the 5E-HY-4B and 10D-HY-8B cultures yielded 18 and 21 mg of 
purified IgG, respectively. SDS - PAGE analysis of these IgG sam-
ples showed two protein bands of 52-kDa heavy chain and 28-kDa 
light chain without any contamination, suggesting a high purity of 
the preparations. Both MoAbs were determined to belong to the 
human IgG2 subclass. MoAb preparations were adjusted to a con-
centration of approximately 2 mg/ml, stored at -20°C, and used 
for further studies. 
IIF study By IIF of normal human skin, the 5E-HY-4B MoAb 
stained the BMZ (Fig 2A), and the 10D-HY-8B MoAb showed an 
identical reactivity. Both MoAbs exhibited similar terminal points 
of reactivity at approximately 0.2-0.4/1g/ml. Ten BP sera used in 
this study as controls demonstrated anti-BMZ reactivity at a titer of 
1: 160-1 : 2560 by IIF (data not shown) . By IIF of 1.0 M NaCI 
split-skin section, the 5E-HY-4B MoAb showed positive reactivity 
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Figure 2. lIF. (A) lIF staining of intact human skin section with the 
5E-HY -4B MoAb displayed a positive staining along the BMZ (magnifica-
tion X400). (B) The SE-HY-4B MoAb also stained the BMZ at the epider-
mal side of a 1.0 M NaCl split-skin section (magnification X400); E, 
epidennis; 0, dennis; C, cleft between epidennis and dennis; BMZ (arrow-
heads). (C) With IIF of cultured KU8 cells, the SE-HY -4B MoAb displayed 
numerous punctate arrays characteristic of hernidesmosomal plaque of 
cultured epithelial cells (magnification X 1000), although (D) the 100-
HY -8B MoAb did not show this reactivity (magnification X 1000). Bar, 10 
/lm. 
along the BMZ of the epidermal side (Fig 2B), and the 10D-HY-8B 
MoAb showed an identical staining. 
When culturecl KU8 cells were used as substrate for IIF, the 
5E-HY-4B MoAb displayed numerous punctate arrays in various 
densities and patterns at the lower cell surface (Fig 2C), which was 
characteristic of hemidesmosomal plaque seen in cultured epithelial 
cells [35], however, the 10D-HY-8B MoAb did not show this posi-
tive reactivity (Fig 2D), even when Triton X-100 extraction was 
omitted. 
Blocking Immunofluorescence Test With the blocking im-
munofluorescence test, the reactivity to the BMZ of the 5E MoAb 
and the 5E-HY-4B MoAb was blocked reciprocally, and the reac-
tivities of the 10D MoAb and 10D-HY-8B MoAb were also 
blocked by each other, however, the reactivity of the 5E-HY-4B 
MoAb was not blocked by the 10D-HY-8B MoAb, nor was the 
reactivity of the lOD-HY -8B MoAb blocked by the 5E-HY -4B 
MoAb. These results well confirmed that both the 5E-HY-4B and 
10D-HY -8B hybridoma cell lines still produce the antibodies with 
the same specificities as those produced by the corresponding origi-
nal EBV -transformed cell lines. 
Immunoblot Analysis With immunoblotting, the 5E-HY-4B 
MoAb exclusively detected a 230-kDa protein, the major BP anti-
gen, at an IgG concentration as low as 20 /1g/ml (Fig 3). In contrast, 
the 10D-HY -8B MoAb did not show any band, even if applied at a 
very high concentration. These results were exactly the same as 
those with the 5E and lOD MoAbs produced by the original EBV 
transformants [22]. Seven BP sera at a dilution of 1 : 40 reacted with 
the 230-kDa band (Fig 3), but three other BP sera recognized a 
170-kDa protein, another known BP antigen (data not shown) . 
Immunoprecipitation To avoid the possibility that the epitope 
for the 10D-HY-8B MoAb might be destroyed or masked during 
the procedures for immunoblotting, we further analyzed the anti-
gen molecules by immunoprecipitation. Approximately 60 /1g 
(30 /11) of each IgG sample was applied on 100-.u1 35S-labe1ed KU8 
cell extract. Both the 5E-HY -4B and lOD-HY -8B MoAbs immuno-
precipitated the 230-kDa BP antigen (Fig 4). Seven BP sera react-
ing with the 230-kDa protein on immunoblotting also precipitated 
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Figure 3. Immunoblot analysis. BP antigen extracted from EDTA-separ-
ated human epidermis was electrophoresed and labeled with human 
MoAbs or 1 : 40 diluted sera from four patients with BP. The SE-HY -4B 
MoAb (20 jig/ml) reacted with a single protein band of approximately 
230-kDa (Iatle 5E), but the IOD-HY-8B MoAb (1 mg/mI) did not show 
any reactivity (Ialle 1OD). Four BP sera reacted with the same 230-kDa 
band (Ialles BP1-BP4) , but control serum did not present a specific band 
(control). Standard molecular markers are indicated on the right. 
the 230-kDa antigen. Three BP sera reacting only with the 170-
kDa protein precipitated neither the 230-kDa protein nor the 170-
kDa protein with immunoprecipitation (data not shown). None of 
the controls, including six normal human sera and culture superna-
tant of the AC-33 cells, precipitated this 230-kDa protein. 
Reactivity with Recombinant Proteins As expected, only the 
SE-HY -4B MoAb and not the lOD-HY -BB MoAb showed a clear 
reactivity with the fusion protein produced by the entire cDNA, 
BPMl (Fig S). Therefore, we further mapped the epitope only for 
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Figure 4. Immunoprecipitation. BP antigen extracted from radiolabeled 
KUS cells was immunoprecipitated using human MoAbs or IO-fil sera 
from four patients with BP, electrophoresed, and analyzed by image 
analyzer. Both the SE-HY-4B and IOD-HY-8B MoAbs (60 fig each; lalles 
5E alld 10D) precipitated a 230-kOa protein. Four BP sera also precipitated 
the 230-kDa protein (lanes BP1-BP4). Two bands with higher molecular 
weight and approximately 200 kDa (arrowheads) are non-specific reac-
tions because these bands are constantly seen in every lane, including the 
control serum (colllrol) . Standard molecular markers are indicated on the 
right. 
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Figure S. Immunoblot analysis of the 120-kDa fusion protein produced 
by BrMl with both the SE-HY-4B and lOD-HY-8B MoAbs. The SE-HY-
4B MoAb strongly reacted with the 120-kDa fusion protein with several 
degradation products (Ialle 5E), although the 10D-HY-8B MoAb did not 
show any reactivity (Ialle 1 OD). Bars on the left indicate standard molecular 
markers, from top to bot/olll, 200, 116, 97, 66, and 4S kDa. 
the SE-HY -4B MoAb by immunoblotting using fusion proteins of 
vanously deleted cDNA clones. The SE-HY-4B reacted with the 
fusion proteins produced by the expression vectors inserted with the 
X-E, X-Bc, and X-S fragments but did not react with the fusion 
proteins of the S-H, X-H, or X-Bg fragments (Fig 6). These 
results indicated that the epitope for the SE-HY -4B MoAb is 
present between the Bg1II and StuI sites of BPM1. This was con-
firmed by the positive reactivity of the SE-HY-4B MoAb with the 
fusion protein of the Bg - S fragment (Fig 6). All results of the 
reactivity of the SE-HY-4B MoAb are summarized in Figure 7A. 
DISCUSSION 
After fusing the SE and 10D transformants with the AC-33 cells, 
we established two stable human -human hybridomas, designated 
SE-HY-4B and 10D-HY-BB. Chromosomal analysis revealed that 
both hybridoma cell lines were tetraploid, although the parental 
AC-33 cells were show~ to have diploid keryotype [24,27]. Further-
more, on Ig heavy-chall1 gene-rearrangement study, each hybri-
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Figure 6. lmmunoblot analysis of fusion proteins produced by variously 
deleted clones of BPMl with the SE-HY-4B MoAb. The SE-HY-4B MoAb 
reacted with the fusion proteins produced by the expression vectors in-
serted with X-E, X-Bc, X-S, and Bg-S fragments as well as the BPMl. In 
contrast, no reactivity was detected with the fusion proteins produced by 
the expression vectors inserted with the S- H, X - H, or X - Bg fragments or 
without insert (Ialle -). Bars on the left indicate standard molecular 
markers, from top 10 bottolll , 93, 69, 46, 30, 22, and 14 kDa. (See text for 
explanation of DNA fragments.) 
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Figure 7. (A) The restriction enzyme map of BPMl, the DNA fragments 
used for the construction of deleted clones, and the reactivity of the 
recombinant proteins produced these deleted clones with the 5E-HY-4B 
MoAb. DNA fragments of S-H, X-H, X-E, X-Bc, X-S, and X-Bg (rec-
taugles) were inserted into pAT153, and a fragment of Bg-S (hatched box) 
was inserted into pGEX-3X. The reactivity of each fusion protein with the 
SE-HY-4B MoAb is indicated on the right. (B) Schematic diagram of the 
structures of desmoplakin I (DPI), the 230-kDa BP antigen (BP A), and the 
region in the 230-kDa BP antigen where the epitope for the SE-HY-4B 
MoAb resides. The region encoded by the cDNA fragment of Bg-S is 
indicated below the structure of BP A by a solid bar. (See text for explana-
tion of DNA fragments_) 
doma line yielded a pattern of rearranged segments derived from the 
AC-33 cells and additional ones derived seemingly from the origi-
nal transformants. The patterns of these additional rearranged seg-
ments differed between the two hybridoma lines. 
Taking these results together, the two new cell lines were consid-
ered to be real hybridomas of the AC-33 cells with the trans for-
mants . Moreover, the MoAbs produced by both hybridomas were 
shown to be synthesized through different rearrangements of Ig 
heavy-chain gene. 
These results showed that this new technique is capable of pro-
ducing human hybridomas stably secreting specific antibodies with 
a relatively high frequency. Because human MoAbs are now impor-
tant for both prophylactic and therapeutic reasons [15,20,24,27,37], 
this technique should be useful for the production of human MoAbs 
in various fields. 
From the culture supernatants of these stable hybridoma cell 
lines, we could obtain a considerable amount of human MoAbs, 
which were highly purified through several column chromatogra-
phies. Using these IgG preparations, we further characterized the 
antigen and epitopes with which these MoAbs reacted. 
The results of blocking immunofluorescence and immunoblot 
analyses in our previous study [22] suggested that the MoAbs pro-
duced by the SE and 10D EBV transformants reacted with distinct 
epitopes. Immunoblot analysis revealed that the SE MoAb recog-
nized the 230-kDa BP antigen, however, the molecule with which 
the 10D MoAb reacted was not determined. In the present study, 
blocking immunofluorescence and immunoblot studies confirmed 
that both hybridomas still produced MoAbs with the same specifici-
ties as those produced by the corresponding original EBV trans for-
mants. Furthermore, immunoprecipitation demonstrated that the 
epitope for the 10D-HY-8B (or 10D) MoAb was present on the 
230-kDa BP antigen. 
Considering these results of immunoblot and immunoprecipita-
tion studies, these two MoAbs are suggested to react with distinct 
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epitopes on the 230-kDa BP antigen: a continuous epitope on this 
protein for the SE-HY-4B MoAb and a conformation-dependent 
epitope for the 10D-Hy-8B MoAb. This speculation was further 
confirmed by the study of the recombinant 230-kDa BP antigen, in 
which the fusion protein produced by the cDNA clone BPMl 
reacted with the SE-HY-4B MoAb but not with the 10D-HY-8B 
MoAb. 
Mueller et al previously showed that although almost all the 
BP sera precipitated the 230-kDa BP antigen with immunoprecipi-
tation, some of the sera did not recognize this antigen with immun-
oblotting [12]. The results of our study suggest that at least one 
explanation for this discrepancy is the presence of a conformation-
dependent epitope on the 230-kDa BP antigen that is detected by 
immunoprecipitation but not by immunoblotting. 
With UF of cultured KU8 cells, the SE-HY-4B MoAb, but not 
the 1 OD-HY -8B MoAb, showed characteristic staining to hemides-
mosomal plaque, although both MoAbs precipitated the 230-kDa 
BP antigen, with immunoprecipitation using the same cells. The 
reason for this discrepancy is not known at present, but this also 
suggests the distinct nature between the epitopes for both MoAbs. 
To further characterize the SE-HY-4B MoAb, we attempted to 
determine more precisely the region of the epitope for this MAb by 
use of fusion proteins produced by a series of deleted clones of 
BPM1. By comparing the reactivity of the SE-HY-4B MoAb with 
seven different fusion proteins, we restricted the epitope for the 
SE-HY-4B MoAb between the BglII and StuI sites of BPM1 (Fig 
7 A). According to the previous report ([38]; see also [23,39,40]), the 
230-kDa BP antigen shows remarkable homology with desmopla-
kin I. In particular, at the C-terminal regions, both molecules have 
176 residue repeats with internal 38 residue motifs; A, B, and C 
domains in desmoplakin I, and Band C domains in the 230-kDa 
BP antigen (Fig 7B). The BglII-StuI fragment ofBPM1 encodes a 
polypeptide with 114 amino acids [23] that corresponds to the area 
with the C-terminal end of the B domain and with the region 
between the Band C domains (Fig 7B). 
Both the pathogenesis and the mechanisms for the abnormal 
autoantibody production in BP are still unknown. The studies using 
both the SE-HY-4B and 10D-HY-8B MoAbs reactive with differ-
ent epitopes on the 230-kDa BP antigen are considered to provide 
us with important information to resolve these issues. Moreover, 
these well-characterized MoAbs shou ld be useful for understanding 
the structure and function of hemidesmosome because the 230-kDa 
BP antigen is one of the few known structural molecules, including 
the 170-kDa BP antigen [41,42] and cx6 1P4 integrin [43,44], of this 
important BMZ adhesive apparatus. 
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